Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.3952W HIGH $16.29
Volume
631.33 K
Value Traded
8.22 M
Short % Float
3.48%
Days to Cover
2.2
+8.56%Week
-20.43%1 Month
-9.48%3 Month
+11.5%6 Month
-49.17%5 Year
+3.29%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
520.00 M
EPS (TTM)
-0.78
P/E Ratio
-
Ent. Value
486.03 M
Total Shares
42.05 M
Float Shares
37.21 M
Insiders
11.52%
Institutions
91.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ANGO Catalyst Timeline
Dated clinical, regulatory and corporate events for AngioDynamics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AngioDynamics, Inc.
342Total events
8Upcoming
56Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲PublicationPresentation
DIRECT study results published in The Oncologist
Stage III pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Full ResultsClinical Data
DIRECT study OS/PFS results reported
Stage III pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Reimbursement / PricingPost-Market
AMA CPT Editorial Panel approves Category I CPT code for open pancreatic IRE
pancreatic tumors (open IRE ablation)source ↗
▲Reimbursement / PricingNanoKnifeApprovedPost-Market
Humana Medicare Advantage updated coverage policy to apply LCD L40205 medical necessity criteria for IRE
prostate and liver cancersource ↗
▲Quarterly UpdateCorporate
AngioDynamics reports fiscal year 2027 first quarter financial results
▲Trial Authorization (CTA / IND)NanoKnifeApprovedEx-US Regulatory
FDA IDE approval for RELIEF study of NanoKnife IRE in BPH
benign prostatic hyperplasiasource ↗
▲Grant / FundingCorporate
Jacobi Hospital selected as ALPHA-PE Research Fund award recipient for investigator-led PE imaging biomarker study
pulmonary embolismsource ↗
◆Quarterly UpdateCorporate
AngioDynamics reports fiscal year 2026 Q4 and full year financial results
▲Reimbursement / PricingPost-Market
Palmetto GBA LCD L40205 effective for prostate and liver IRE
favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liversource ↗
▲IND ClearanceIND
FDA IDE Approval for RELIEF Feasibility Study
Benign Prostatic Hyperplasia (BPH)source ↗
◆Oral PresentationPresentation
AngioDynamics to present at Goldman Sachs 47th Annual Global Healthcare Conference
▲Other Regulator MilestoneEx-US Regulatory
Medicare coverage framework takes effect for NanoKnife IRE
prostate and liver cancersource ↗
◆Oral PresentationPresentation
Presentation of two-year PRESERVE data at AUA 2026 Annual Meeting
intermediate-risk prostate cancersource ↗
▲Full ResultsClinical Data
Two-year PRESERVE trial data demonstrating durable outcomes for NanoKnife IRE System
intermediate-risk prostate cancersource ↗
◆Oral PresentationPresentation
AngioDynamics management to present at 25th Annual Needham Virtual Healthcare Conference
◆Oral PresentationPresentation
AngioDynamics to present at Leerink Partners Global Healthcare Conference
◆Oral PresentationPresentation
AngioDynamics to present at 44th Annual J.P. Morgan Healthcare Conference
▲IP Litigation RulingIP / Competition
Federal Circuit affirmed invalidation of Bard's power injectable port patents, concluding litigation
▲Other Regulator MilestoneEx-US Regulatory
IRE CPT codes for prostate and liver effective
prostate tissue ablationsource ↗
▲Reimbursement / PricingPost-Market
Category I CPT codes for liver (47384) and prostate (55877) IRE implemented
liver and prostate IREsource ↗
▲Trial Authorization (CTA / IND)Ex-US Regulatory
FDA IDE approval for APEX-Return study evaluating AlphaReturn Blood Management System with AlphaVac F1885 MMA System
acute pulmonary embolismsource ↗
▲IND ClearanceIND
FDA IDE approval for APEX-Return pivotal study
acute intermediate-risk pulmonary embolismsource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA 510(k) clearance for modified AlphaVac F1885 System expanded indications
venous thromboembolism including pulmonary embolismsource ↗
▲Full ResultsClinical Data
PRESERVE study results published in European Urology
Intermediate-risk prostate cancersource ↗
▲First Patient DosedAuryonTrial
First patient enrolled in AMBITION BTK trial
Critical Limb Ischemia (below-the-knee lesions)source ↗
▲First Patient DosedTrial
First patient enrolled in RECOVER-AV clinical trial
Acute intermediate-risk pulmonary embolismsource ↗
●Milestone PaymentCorporate
Final revenue performance-based milestone payment of $5.0M made for Auryon acquisition
●Debt Royalty FinancingCorporate
AngioDynamics enters into $25M revolving line of credit with J.P. Morgan
▲Timing GuidancePresentation
Expects positive operating cash flow in Q4 fiscal 2025 and cash around $55 million
▲Trial InitiationAuryonTrial
Initiated AMBITION BTK RCT and Registry for Auryon in critical limb ischemia below the knee
critical limb ischemia below the kneesource ↗
▲Full ResultsAlphaVacClinical Data
Publication of APEX-AV trial results in JSCAI for AlphaVac F1885 System
pulmonary embolismsource ↗
▲FDA ApprovalNanoKnifeApprovedFDA Decision
FDA clearance for NanoKnife System for prostate tissue ablation
prostate tissue ablationsource ↗
▲Timing GuidancePresentation
Increased fiscal year 2025 guidance for net sales, Med Tech growth, gross margin, adjusted EBITDA, and adjusted EPS
▲Debt Royalty FinancingCorporate
Secured $25 million revolving line of credit from J.P. Morgan
●Oral PresentationPresentation
Virtual cardiovascular investor event to be held after Q3 fiscal 2025 earnings call
◆Enrollment UpdateAuryonTrial
Patient enrollment beginning Q2 CY2025 for coronary artery disease RCT and registry
Coronary Artery Diseasesource ↗
●Oral PresentationNanoKnifeApprovedPresentation
Virtual NanoKnife Investor Event hosted on January 8, 2025
prostate tumorssource ↗
▲Timing GuidancePresentation
Company expects to be Adjusted EBITDA positive for fiscal year 2025
▲FDA ApprovalNanoKnifeApprovedFDA Decision
NanoKnife receives FDA approval for prostate indication
prostate cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How ANGO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 95%
Micro Cap(rank 624 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ANGO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NanoKnife IRE System | intermediate-risk prostate cancer | 2026-05-13 | 80% freedom-from-treatment-failure rate among protocol-biopsied patientsRead More | AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Nighan Warren JROfficer (SVP Quality and Regulatory) | Sell | -23,370 64,745 held | $14.72 | 07/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANGO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.9 % (350 %) | 8.02 M | 768.50 K | 241.56% ( 543.50 K) |
ANGO Institutional Ownership Trends
ANGO Short Interest
Shares sold short, counted twice a month.
3.48%
Short % of Float
of tradable shares sold short
1.3M
Shares Sold Short
-3.6% vs prior count
2.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
581.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANGO ranks across every disease it competes in
Competitive Position is a premium feature
See how ANGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANGO News
ANGOAngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE
AngioDynamics announced the publication of the DIRECT study, which found that an irreversible electroporation (IRE) treatment strategy led to longer overall survival in Stage III pancreatic cancer patients. Additionally, a new Category I CPT code for open pancreatic IRE will take effect on January 1, 2027, improving the reporting of this procedure.
Read more →ANGOAngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
AngioDynamics announced that Humana has updated its Medicare Advantage coverage policy to include Local Coverage Determination (LCD) L40205 criteria for irreversible electroporation (IRE). This update aims to broaden access to NanoKnife® IRE for patients with prostate and liver cancer, enhancing treatment options and patient care.
Read more →ANGO▼ -20.9%on this news
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
AngioDynamics, Inc. announced its financial results for the first quarter of fiscal year 2027, reporting net sales of $80.9 million. This reflects a year-over-year growth, indicating the company's effective execution of its strategy in the medical technology sector. The company aims to enhance cancer treatment and restore healthy blood flow in patients.
Read more →ANGO▼ -20.9%on this newsshared move
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
AngioDynamics has announced the appointment of Eric Honroth as its new President and CEO, effective November 2, 2026. He will succeed Jim Clemmer, who is leaving the Board of Directors. This leadership change is expected to guide the company in its mission to improve patient care and expand treatment options.
Read more →ANGOAngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
AngioDynamics has announced that Jacobi Hospital in Bronx, New York, has been awarded the ALPHA-PE Research Fund. This award supports an independent study led by Dr. Jonathan Alis and Dr. Seth I. Sokol, aimed at advancing real-world evidence for the treatment of pulmonary embolism. The initiative is in collaboration with The PERT Consortium.
Read more →ANGOAngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
AngioDynamics, Inc. has announced that it will report its financial results for the first quarter of fiscal year 2027 on October 8, 2026. The report will be released before the market opens, followed by a conference call at 8:00 am ET to discuss the results. This event highlights the company's ongoing commitment to transparency and communication with stakeholders.
Read more →ANGOAngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics, Inc. (NASDAQ: ANGO) has announced its participation in several upcoming investor conferences, including the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. This engagement reflects the company's commitment to connect with investors and stakeholders. The focus on restoring healthy blood flow and expanding cancer treatment options is central to their mission.
Read more →ANGOAngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
AngioDynamics, Inc. reported record financial results for the fourth quarter and full year of fiscal year 2026, ending May 31, 2026. The company highlighted significant year-over-year growth in its medical technology sector, contributing to improved profitability. This performance underscores AngioDynamics' commitment to enhancing patient care and expanding treatment options.
Read more →ANGOAngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
AngioDynamics has announced the date for its fiscal 2026 fourth quarter and full-year financial results, which will be reported on July 14, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders are likely to monitor these results for insights into the company's financial performance.
Read more →ANGOAngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
AngioDynamics has received FDA Investigational Device Exemption (IDE) approval for its RELIEF feasibility study. This study will evaluate the NanoKnife IRE platform as a minimally invasive treatment for benign prostatic hyperplasia (BPH). The approval marks a significant step in exploring new treatment options for patients suffering from BPH.
Read more →ANGOAngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
AngioDynamics has announced an expansion of patient access to its NanoKnife IRE technology for treating prostate and liver cancer. This initiative coincides with the implementation of a new Medicare coverage framework, which is expected to enhance treatment options for patients. The move aims to improve patient outcomes and broaden the availability of this innovative technology.
Read more →ANGOAngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
AngioDynamics is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference. The event will provide a platform for the company to discuss its strategies and future directions in the healthcare sector. Details regarding the presentation's content and timing are yet to be disclosed.
Read more →ANGOAngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
AngioDynamics has announced data from the two-year PRESERVE trial, which evaluates the outcomes of the NanoKnife IRE system in treating intermediate-risk prostate cancer. The results indicate the system's durability and effectiveness in this patient population. Further details on the trial's findings and implications for clinical practice were not provided.
Read more →ANGO▼ -13.7%on this news
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
AngioDynamics has reported its financial results for the third quarter of fiscal year 2026, highlighting sustained double-digit growth in the Med Tech sector. The company continues to demonstrate profitability, reflecting its strong market position. This positive performance underscores AngioDynamics' resilience and effective business strategies.
Read more →ANGOAngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
AngioDynamics, Inc. will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 8:45 a.m. (ET). The event will be accessible via a live webcast on the company's website, which will also offer a replay afterward. This presentation underscores AngioDynamics' role in advancing medical technology and patient care.
Read more →ANGOAngioDynamics to Present at the Leerink Partners Global Healthcare Conference
AngioDynamics, Inc. will present at the Leerink Partners Global Healthcare Conference on March 9, 2026. CEO Jim Clemmer will lead the presentation, which aims to showcase the company's advancements in medical technology. A live webcast will be available for those interested in the event.
Read more →ANGOAngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
AngioDynamics and The PERT Consortium have launched the ALPHA-PE Research Fund to support independent research in pulmonary embolism (PE) care. This initiative aims to address critical evidence gaps by funding investigator-led studies that focus on patient outcomes and innovative treatment approaches. Grants will range from $50,000 to $750,000, fostering collaboration within the cardiovascular community.
Read more →ANGOAngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
AngioDynamics is set to host its third Cardiovascular Scientific Forum from February 6-8, 2026, in Fort Lauderdale, Florida. The event will gather cardiovascular leaders to discuss emerging technologies and clinical evidence. Recent FDA approvals for the AlphaReturn Blood Management System and AlphaVac F1885 System highlight the company's commitment to advancing cardiovascular care.
Read more →ANGOJ.P. Morgan 44th Annual Healthcare Conference
AngioDynamics showcased its forward-looking strategy at the J.P. Morgan 44th Annual Healthcare Conference, emphasizing its positioning for sustained growth in the MedTech space. The company highlighted its successful products, including Auryon, which has seen significant sales and usage since its launch. However, management acknowledged various risks, including competition, regulatory challenges, and ongoing litigation that could impact future performance.
Read more →ANGO▼ -13.5%on this news· ran to -25% by day 3
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
AngioDynamics, Inc. announced its financial results for the second quarter of fiscal year 2026, reporting an 8.8% increase in net sales, driven primarily by a 13.0% growth in its Med Tech segment. The company achieved important FDA approvals for new studies and expanded product capabilities, contributing to its optimism for sustained growth. However, it recorded a GAAP net loss of $6.4 million during the quarter. The successful conclusion of a protracted litigation with C.R. Bard also bolstered the company's position as it moves forward in fiscal 2026.
Read more →About AngioDynamics, Inc.
Headquarters14 PLAZA DRIVE, LATHAM, NY, 12110
Founded1988
BIOPHARMAWATCH ELITE PLUS
Trade the next ANGO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime